NEWS & COMMENTS

PROHOST    FILTER

 MEDAREX (MEDX)

    More and more firms are allying with Medarex to develop their dream products. The latest comr is Oxford Genome Sciences (UK) Ltd "OGeS". The firms announced that they have entered into a strategic collaboration to discover and develop new human antibody therapeutics for the treatment of cancers, including colorectal cancer. The collaboration combines OGeS' ability to discover novel targets for oncology with Medarex's expertise in the development of fully human antibody therapeutics. The collaboration provides for OGeS and Medarex to discover, develop and commercialize therapeutic antibodies on a 50:50 basis. Other financial terms of the agreement were not disclosed.

READ MORE: Oxford Genome Sciences and Medarex Sign Therapeutic Antibody Collaboration Agreement in Cancer

-------------------------------------

TLR AND RNAi Technologies

     RNAi and Toll-like receptor drug developer driug developers are followed up by Prohost. There are around six visible firms in this group. (Read Prohost publications). The following two members of the group announced news.  

ALNYLAM (ALNY)

     While reporting its consolidated financial results for the quarter ended March 31, 2006, Alnylam, which is a pioneer in RNAi therapeutic technology, elaborated on its plans and progresses. Considerable progress seems to be made, including a significant increase in revenue due to R&D funding from our pharmaceutical alliances, which the firm expect to form the basis for continued and sustainable revenues over the next several years. The report revealed that the firm’s lead product, ALN-RSV01, which is an RNAi therapeutic for the treatment of RSV infection, was found safe and well tolerated in Phase I trials, setting the stage for further development of this program. It referred to signing another alliance with Novartis for pandemic flu – the firm’s  fifth major alliance to date. Other important scientific achievements have also been reported.

READ MORE: Alnylam Pharmaceuticals Reports First Quarter 2006 Financial Results; Company Achieves Multiple Milestones and Recognizes Increased Revenue from Pharmaceutical Partners

ANADYS (ANDS)  

     Anadys Pharmaceuticals reported its operational highlights and financial results for the quarter ended March 31, 2006. Besides the finances (click on the link below), the firm mention the initiation of dosing of its product  ANA975, a Toll-Like Receptor-7 oral prodrug, in chronic hepatitis C virus patients in Phase Ib clinical trial.It confirmed good news that its product ANA380 has achieved viral load reduction in Lamivudine-Resistant hepatitis B patients in Phase II Clinical Trial.  The firm added news about new appointments of executive managers and scientists and more.       

READ DETAILS: Anadys Pharmaceuticals Reports First Quarter 2006 Financial Results

Prohost is independent publication providing information on biotech companies. Prohost does not accept compensation from companies that are featured or profiled. It is strongly recommended that any purchase or sale decisions to any of the featured companies be discussed with a financial advisor or broker prior to completing any such purchase or sale decision. All statements or expressions are the opinion of Prohost and are not meant to be a solicitation or recommendation to buy, sell, or hold securities. Investing in embryonic companies, micro-cap and growth securities is highly speculative and carries a high degree of risk. It is possible that an investor can lose all of his/her investment in this type of companies that are profiled. The information that Prohost relies on is either through the profiled company, news services, research reports, interviews, or other outside sources that Prohost believes are reliable. Prohost makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure of the profiled companies and accepts no responsibilities for inaccuracies or misleading content in any material supplied by those clients. There can be no assurance that future events relating to the profiled company will occur as anticipated. The information contained herein is provided as an information service only. Past performance of featured companies does not guarantee the future success of any currently featured or profiled company. We encourage our readers to invest carefully and read the investor information provided by the Securities and Exchange Commission ("SEC") and/or the National Association of Securities Dealers ("NASD"). We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at: http://www.sec.gov/consumer/cyberfr.htm